自2000年以来,林业发展局批准的新药物有一半以上依靠由卫生研究所资助的研究,现在受到预算削减提案的威胁。 Over half of new FDA-approved drugs since 2000 relied on NIH-funded research now threatened by proposed budget cuts.

在《科学》上发表的一份新研究报告发现,自2000年以来,林业发展局核准的小分子药物有一半以上与NIH资助的研究有关,其中51.4%与风险项目有关,而预算削减幅度为40%。 A new study published in Science finds that over half of the small-molecule drugs approved by the FDA since 2000 are linked to NIH-funded research, with 51.4% tied to projects at risk under a proposed 40% budget cut. 虽然只有7.1%的核准药物直接引用了国家卫生研究所风险赠款,但59.4%引用了国家卫生研究所支持的研究,强调了联邦资金在促成医疗创新方面的关键作用。 While only 7.1% of approved drugs directly cited at-risk NIH grants, 59.4% referenced NIH-supported studies, highlighting the critical role of federal funding in enabling medical innovation. 研究强调,公共资助项目的基础科学是现代药物发展的大部分基础,即使这种联系是间接的。 The research underscores that foundational science from publicly funded projects underpins much of modern drug development, even when connections are indirect. 专家们警告说,大幅度削减可能会破坏新治疗的管道,阻碍未来的突破,削弱美国在生物医学方面的领导作用,同时强调基本研究经费不足的长期风险。 Experts warn that deep cuts could disrupt the pipeline of new treatments, hinder future breakthroughs, and weaken U.S. leadership in biomedicine, emphasizing the long-term risks of underfunding basic research.